The 26th running of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held this year in Amsterdam, Netherlands, attracted 11 350 participants from 123 countries. Marco De Ambrogi, John McConnell, and Ammara Mushtaq report on the meeting highlights.

Ridinilazole for *Clostridium difficile* infection {#cesec10}
==================================================

Mark Wilcox (Leeds Teaching Hospital, Leeds, UK) and colleagues presented results of a phase 2, double blind trial of ridinilazole versus vancomycin for treatment of *C difficile* infection (the CoDIFy trial; ePoster 0177). Ridinilazole is an orally administered, non-absorbable, narrow-spectrum antibiotic that is active against multiple strains of *C difficile*. 100 patients with laboratory confirmed *C difficile* infection were randomly assigned to treatment for 10 days with ridinilazole (200 mg, twice a day) or vancomycin (125 mg, four times a day). The primary efficacy endpoint was sustained clinical response, defined as response at the end of treatment with no disease recurrence for the next 30 days, in the modified intention-to-treat (mITT) population. Of 36 patients in the mITT population who received ridinilazole, 24 (67%) achieved sustained clinical response versus 14 (42%) of 33 who received vancomycin, demonstrating superiority of ridinilazole. Improvement in sustained clinical response with ridinilazole was attributed to a lower rate of recurrent *C difficile* infection in this group (14%) compared with the vancomycin-treated group (35%). Adverse events and serious adverse events were similar in the two treatment groups at about 80% and 17%, respectively. Summit Therapeutics, the company developing ridinilazole, has announced that the drug has been granted Fast Track status by the US Food and Drug Administration.

Long-term bedaquiline treatment {#cesec20}
===============================

Lorenzo Guglielmetti (Sorbonne University, Paris, France; abstract 7614) and colleagues presented data on the French national cohort of all patients treated for at least 30 days with bedaquiline for multidrug-resistant tuberculosis between January 2011 and December 2013. Bedaquiline is recommended for a maximum treatment duration of 24 weeks; however, in the cohort of 44 patients, treatment ranged from 31 to 768 days, with a median of 360 days, and 41 patients received more than 24 weeks of bedaquiline. In addition to bedaquiline, patients were most often treated with linezolid, para-aminosalicylic acid, cycloserine, amikacin, imipenem-amoxicillin/clavulanic acid, and moxifloxacin. Median duration of all drug treatment was 627 days. 32 patients had successful treatment outcomes, eight were lost to follow-up or not evaluated, three died, and one failed treatment. Two patients discontinued bedaquiline because of raised QT intervals, but no arrhythmias or symptomatic cardiac side-effects occurred.

Colistin resistance {#cesec30}
===================

Despite being first reported less than 5 months before ECCMID (see *Lancet Infect Dis* 2016; **16:** 161--68), the plasmid-mediated colistin-resistance gene *mcr-1* featured prominently at the meeting. Farid El Garch (Vétoquinol, Lure, France; abstract 7426) and colleagues found the gene in 42 (0·67%) of 6274 *Escherichia coli* isolates and three (0·4%) of 748 *Salmonella* spp isolates obtained from pigs and cattle between 2004 and 2014. The isolates came from France, Italy, Germany, and Belgium. No increase in prevalence of *mcr-1* over the survey period was found. Kees Veldman (Wageningen University, Wageningen, Netherlands; abstract 7430) and colleagues looked for the *mcr-1* gene in their collection of 12 265 *Salmonella* spp isolates and 11 380 *E coli* isolates from animal, food, and human sources between 2010 and 2015. 13 *Salmonella* spp isolates, all from poultry, were positive, as were 26 *E coli* from faecal samples of livestock and 63 from meat. The gene was not found in human isolates. But Liz Terveer (Leiden University Medical Centre, Leiden, Netherlands; abstract 7590) and colleagues showed that the gene is present in human bacterial isolates in the Netherlands, when they tested 624 faecal samples obtained from patients admitted to their hospital during the first 6 months of 2015, and found two (0·3%) positive for *mcr-1*. The *mcr-1*-positive *E coli* cultured from one of these samples was colistin susceptible, and no Enterobacteriaceae could be cultured from the second positive sample.

Medical students\' knowledge of antibiotic prescribing {#cesec40}
======================================================

Are medical students confident about their skills in antibiotic prescribing? Oliver Dyar (Karolinska Institute, Stockholm, Sweden; oral presentation E069) presented the results of the Student-PREPARE project designed to answer this question, which surveyed 7432 students in 224 medical schools across Europe. Whereas most felt able to recognise clinical signs of infection, determine severity, and distinguish bacterial from viral upper respiratory tract infections, only about 50% were sufficiently prepared to decide the shortest adequate duration of treatment, use surgical antibiotic prophylaxis principles, and measure antibiotic use and interpret results of such studies. Students in countries with the worst resistance rates tended to have the greatest need for more education on antibiotic prescribing.

Microbiota in disease process {#cesec50}
=============================

Debby Bogaert (University Medical Center Utrecht, Netherlands; abstract 5035) described that, at the individual level, in 17 children with cystic fibrosis studied there was limited concordance between nasopharyngeal and oropharyngeal microbiota and their corresponding broncho-alveolar lavage microbial composition. Researchers concluded that to direct therapy lower respiratory tract should be sampled in cystic fibrosis patients with lower respiratory tract infection. Dalia Khalil (Karolinska University Hospital, Stockholm, Sweden; abstract 730) presented the study determining the effect of a single dose of amoxicillin---as is used before dental procedures---on oral microbial composition and their resistance. Stimulated salivary samples were obtained before and after administration of 2 g amoxicillin. A significant ecological disturbance was observed in oral microflora: *Streptococcus salivarius* and other viridans streptococci reduced while *Neisseria* spp increased. Furthermore, there was also reduced susceptibility to amoxicillin in viridans streptococci after the intervention. "Even a single dose of antibiotics may pose a risk for the development and dissemination of antibiotic resistance", Khalil concluded. Maysa Laurena Maria van Doorn-Schepens (Vu University Medical Centre, Amsterdam, Netherlands; abstract 6043) presented the study on the effect of selective digestive tract decontamination (SDD) on potentially pathogenic microorganisms. A total of 118 patients with colorectal carcinoma were included: 55 randomly assigned to receive SDD and 63 in the control group that did not have SDD. Composition and abundance of Proteobacteria and some commensal species from the phylum Firmicutes were affected by SDD. Doorn-Schepens concluded "SDD elicits not only major shifts in pathogenic members, but also on important health-associated, commensal gut species".

CAESAR: antimicrobial resistance surveillance programme {#cesec60}
=======================================================

Nienke van de Sande-Bruinsma (WHO Regional Office for Europe, Copenhagen, Denmark; oral presentation S203) presented results from the Central Asian and Eastern-Europe Surveillance of Antimicrobial Resistance or CAESAR, that includes countries not covered by the European Antimicrobial Resistance Surveillance Network (EARS-Net). Data from each country was reported with a "level-of-evidence" of A, B, or C, with level A being "adequate assessment of the magnitude and trends of antimicrobial resistance in the country". Data from Switzerland and Turkey had level A evidence. In Switzerland, 8% and 17% of *E coli* and 8% and 6% of *Klebsiella pneumoniae* were resistant to third-generation cephalosporins and fluoroquinolones, respectively. None of the *E coli* and 1% of *K pneumoniae* were resistant to carbapenems. For *Pseudomonas aeruginosa*, 8%, 11%, 9%, and 10% of isolates were resistant to fluoroquinolones, piperacillin/piperacillin-tazobactam, ceftazidime and carbapenems, respectively. Resistance in *Acinetobacter* spp was 7%, 11%, and 5% to amikacin, fluoroquinolones, and carbapenems, respectively. Similarly, in Turkey, 36% and 47% of *E coli* and 52% and 42% of *K pneumoniae* were resistant to third-generation cephalosporins and fluoroquinolones, respectively. Of note, 1% of *E coli* and 28% of *K pneumoniae* were resistant to carbapenems. For *P aeruginosa*, 19%, 21%, 19%, and 24% of isolates were resistant to fluoroquinolones, piperacillin/piperacillin-tazobactam, ceftazidime, and carbapenems. High levels of resistance were observed in *Acinetobacter* spp from Turkey: 57%, 89%, and 89% isolates were resistant to amikacin, fluoroquinolones, and carbapenems, respectively. The rate of meticillin resistance in *Staphylococcus aureus* was 5% in Switzerland and 27% in Turkey.

Risk factors of nosocomial outbreaks of MERS-CoV {#cesec70}
================================================

Since the first description of Middle East respiratory syndrome coronavirus (MERS-CoV) in September 2012, 1698 cases have been documented from 26 countries with a mortality of 35·9%, as of April 8, 2016. 42% of cases are health-care acquired, "showing that nosocomial transmission contributes to a significant proportion of cases", said David Shu Cheong Hui (The Chinese University of Hong Kong, Hong Kong, China; oral presentation S449). For the initial Jordanian outbreak, infection control measures were suboptimal resulting in transmission of disease from the index case to ten health-care workers. However, Hui noted that infection control measures during the same outbreak at two other transfer hospitals were sufficient and transmission to health-care workers was not observed. Reviewing risk factors in individual nosocomial outbreaks of MERS-CoV in Jordan, Al-Hasa, UAE, Jeddah, and South Korea, Hui summarised that overcrowding, inadequate ventilation, suboptimal infection control, and poor contact tracing were common risk factors in all outbreaks, much similar to SARS. "Doctor shopping"---a culture of changing providers---appeared to be a unique risk factor in the South Korean outbreak.

Ceftazidime-avibactam in the treatment of multidrug-resistant Gram-negative bacteria {#cesec80}
====================================================================================

Gram-negative pathogens are increasingly resistant to most available antibiotics so new solutions to treat the infections that they cause are warranted. Angela Wardman (AstraZeneca PLC, Alderley Park, UK; abstract 2332) presented the results of a pooled analysis of seven trials assessing the efficacy of ceftazidime-avibactam against ceftazidime-resistant Gram-negative pathogens. This new drug combination was tested to circumvent resistance to ceftazidime, a cephalosporin, in multidrug-resistant *P aeruginosa*, carbapenem-resistant Gram-negative pathogens and extended-spectrum β-lactamase-producing Enterobacteriaceae. The data analysed included the results of the REPRISE study, presented in this issue, which was the only open-label trial comparing ceftazidime-avibactam with best available therapy. Overall, 79% (n=308) of patients with ceftazidime-resistant Enterobacteriaceae demonstrated a favourable response to ceftazidime-avibactam compared with 82% (n=719) of patients with ceftazidime-susceptible pathogens. Although the numbers are small, 77% (n=25) of patients with ceftazidime-resistant *P aeruginosa* responded to ceftazidime-avibactam compared with 86% (n=57) of patients with ceftazidime-susceptible pathogens. Ceftazidime-avibactam showed similar efficacy and safety to the comparator so it could be used as a potential alternative to carbapenems in patients with ceftazidime-resistant Enterobacteriaceae and *P aeruginosa*.

Infectious disease control in migrant populations {#cesec90}
=================================================

Hilary Kirkbride (Public Health England, London, UK; oral presentation S548) presented the results of screening for infectious diseases in migrants in the UK. Much of the burden of infectious diseases in the UK falls on the non-UK born population (70% of tuberculosis cases, 50% of HIV cases, 60% of malaria cases) but there is very limited evidence that migrants constitute a threat for the local population. Marty Cetron (Centers for Disease Control and Prevention, Atlanta, GA, USA; oral presentation S549) described the US approach to pre-entry screening and its cost-effectiveness. Tuberculosis screening, anthelmintic treatment, and vaccination in the country of origin before migration to the USA were reported to be cost-effective. Irene Veldhuijzen (National Institute for Public Health and the Environment, Bilthoven, Netherlands; oral presentation S550) reported data that almost 50% of hepatitis B cases diagnosed in the Netherlands are in migrants. Moreover, the HepScreen Program, which involved seven European countries and assessed outcomes and cost of different screening models for hepatitis B showed that the highest uptake was for screening in health-care centres, whereas screening in workplaces and universities was the most cost-effective strategy. Teymur Noori (European Centre for Disease Prevention and Control, Stockholm, Sweden; oral presentation S551) described a new project for developing screening guidelines for infectious diseases in migrants for European countries, which will necessarily include post-entry screening to cover undocumented migrants.

Use of ivermectin for treating dengue {#cesec100}
=====================================

At present there is no available therapy for patients infected by dengue virus, apart from supportive care. Panisadee Avirutnan (Siriraj Hospital, Bangkok, Thailand; oral presentation S634) presented the results of a phase 2, randomised, double-blind, placebo-controlled trial to assess the anti-dengue viral replication efficacy and safety of oral ivermectin, a widely used oral anthelmintic agent, at a dose of 300--400 μg/kg for 2--3 days at two hospitals in Thailand. The primary endpoints were dengue viraemia and dengue NS1 antigenaemia clearance. The median areas under the viraemia curve until NS1 antigenaemia clearance were 15·08, 10·90, and 7·60 log~10~ copies per mL per day in placebo, 2-day, and 3-day ivermectin groups, respectively. The median NS1 clearance times were 107·9 h, 85·0 h, and 59·5 h in the placebo, 2-day, and 3-day ivermectin groups, respectively. Rates of adverse events were similar in all treatment groups. Ivermectin is now being tested in a larger phase 3 trial to assess specific clinical outcomes.

Critical appraisal of new antibiotics {#cesec110}
=====================================

David Paterson (University of Queensland Centre for Clinical Research, Brisbane, Australia; oral presentation S329) discussed newly available combination drugs such as ceftazidime-avibactam and ceftalozane-tazobactam, which have been developed to treat multidrug-resistant Gram-negative infections. Data are still warranted on the use of these drugs in critically ill patients or patients with pneumonia, development of resistance, and induced risk of *C difficile* infection. Angela Huttner (University of Geneva, Geneva, Switzerland; oral presentation S330) discussed new oxazolidinones and glycopeptides that are becoming available. Some molecules, such as dalbavancin and oritavancin that are now indicated for skin infections, have actually been either re-purposed or re-discovered. Tedizolid instead is a new oxazolidinone licensed for treating skin infections but data are lacking on possible enhanced risk of clostridium infection. Ursula Theuretzbacher (University of Wien, Wien, Austria; oral presentation S332) discussed some of the new antibiotics that are expected to emerge from the pipeline within the next 10 years. Pleuromutilins are a class of natural products originally discovered in 1950 that are now being developed to treat community-acquired pneumonia. Type II topoisomerase inhibitors such as gepotidactin and zoliflodacin act on the same target as quinolones and are being developed to treat gonorrhoea.

For **full details of the ECCMID programme** see <http://eccmidlive.org/#events/25/programs/2016-04-09>
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